NCT07055529View on ClinicalTrials.gov

Comparison of Efficacy and Safety Psoralen Combined With Ultraviolet A (PUVA) Vs Tofacitinib in the Treatment of Generalized Vitiligo.

EARLY_PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 1, 2025

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions

Vitiligo, Generalized

Interventions

DRUG

Group A recieving PUVA therapy

This group A will recieve PUVA therapy twice weekly for 6 months

DRUG

Group B receiving Tablet Tofacitinib

This group will be given tablet Tofacitinib 5mg twice daily for 6 months

Trial Locations (1)

25000

MTI-HMC Peshawar, Peshawar

All Listed Sponsors

lead

Hayat Abad Medical Complex, Peshawar.

OTHER_GOV

NCT07055529 - Comparison of Efficacy and Safety Psoralen Combined With Ultraviolet A (PUVA) Vs Tofacitinib in the Treatment of Generalized Vitiligo. | Biotech Hunter | Biotech Hunter